Notably, vaccine recipients with a prior COVID-19 history showed significantly stronger IGRA reactivities (1117•0 [95% CI 836•5–1491•0] pg/mL) indicating the presence of more SARS-CoV-2 spike protein-specific T cells compared to COVID-19 naïve vaccine recipients (620•6 [95% CI 460•2–836•9] pg/mL, t-test p<0•05; Fig. 2a). The gene discussed is CHMP5; the disease is COVID-19.